IVIG-eye Drops Treatment for Dry Eye Disease

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-05-01

Study Completion Date

2019-08-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to establish whether patients with Dry Eye Disease are able to safely tolerate receiving Intravenous Immunoglobulin (IVIG) eye drops two times a day for eight weeks (primary 'safety and tolerability' objective). The exploratory objective is to investigate the preliminary efficacy of the use of IVIG eye drops in treating Dry Eye Disease (exploratory efficacy objective) to estimate the effectiveness of the trial intervention and collecting data to inform the design of a future definitive trial.

This will be a Randomized controlled trial, in which a total of 28 subjects will be enrolled at 1 clinical site. Subjects will be randomly assigned to one of two groups (#1, #2), with 14 subjects per group. One group will be given placebo (Normal saline eye drops) and the other group will be given eye drops containing the study drug (IVIG).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

OSIG-eye Drops Treatment for Dry Eye Disease

NCT04510428

Dry Eye

WITHDRAWN PHASE2

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

NCT01733992

Keratoconjunctivitis Sicca

COMPLETED PHASE1

A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

NCT04030962

Dry Eye Disease Dry Eye Syndrome

COMPLETED PHASE1/PHASE2

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

NCT05586152

Dry Eye Disease

COMPLETED PHASE1/PHASE2

Phase 3 Study of EBI-005 in Dry Eye Disease

NCT01998802

Dry Eye Disease (DED)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IVIG-Eye Drop

Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks

Group Type EXPERIMENTAL

Intravenous Immune Globulin (IVIG)

Intervention Type DRUG

Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks

Placebo-Eye Drop

Normal Saline Eye Drops (0.9% NaCl)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intravenous Immune Globulin (IVIG)

Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks

Intervention Type DRUG

Placebo

Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Sign and date the informed consent form approved by the Institutional Review Board (IRB)
2. ≥ 18 years of age
3. Demonstrate at least any 2 of the following signs in the same eye or a sign and symptom.

1. Conjunctival staining present ≥ 1 (out of possible score of 6 per eye)
2. Corneal staining present ≥ 2 (out of a possible score of 15 per eye)
3. Tear film break up time (TFBUT) ≤ 7 seconds
4. Schirmer's test ≥ 0 to ≤ 9 mm/5min
5. Superior Limbic Keratoconjunctivitis (SLK) pattern staining ≥ 1
6. Meiboscale grade ≥ 2
7. Validated Bulbar Redness ≥ 40
8. Demonstrate symptoms of dry eye disease Ocular Surface Disease Index (OSDI) score of at least ≥ 13.
9. Demonstrate Symptom Intensity Assessment of ≥ 3.
4. Patient reported dry eye-related ocular symptoms for at least 6 months before the Screening Visit and use or desire to use artificial tears on average 2 times per day in the 2 weeks preceding the screening visit
5. Intraocular pressure (IOP) ≥ 5 mmHg and ≤ 22 mmHg in each eye
6. Women of child-bearing potential must agree to use a reliable method of contraception during study participation and must demonstrate a negative pregnancy test at the Screening Visit
7. Be willing/able to return for all study visits and to follow instructions from the study investigator and his/her staff
8. Ocular Surface Wash Anti-Citrullinated Protein Antibody (ACPA) value of \> 4.4 units in either eye at any time in the past.

Exclusion Criteria

1. Allergic to IVIG or any similar products, or excipients of IVIG eye drops 4 mg/ml.
2. Use of contact lenses within the last 2-weeks prior to the baseline Visit.
3. Use of Allogenic serum or plasma eye drops within the last 2-weeks prior to the baseline Visit.
4. Unwilling to commit to no use of contact lenses for the duration of the study.
5. Pregnant or nursing/lactating
6. Participation in a study of an investigational drug or device within the 30 days preceding the Screening Visit
7. Current diagnosis of any of the following ocular conditions:

i) Acute allergic conjunctivitis ii) Active infection (e.g. bacterial, viral, protozoan or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids) iii) Active intraocular inflammation (e.g., retinitis, choroiditis, uveitis)
8. A cognitive or psychiatric deficit that precludes informed consent or ability to perform
9. Vulnerable populations, such as neonates, pregnant women, children, prisoners, institutionalized individuals, or others who may be considered vulnerable populations.
10. Have active drug/alcohol dependence or abuse.
11. The corneal epithelial defect is larger than 1 mm2 in either eye.
12. Active ocular infection or ocular allergies.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No